These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33915863)

  • 1. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation.
    Castro LS; Lobo GS; Pereira P; Freire MG; Neves MC; Pedro AQ
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33915863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceuticals from microorganisms: from production to purification.
    Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
    Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.
    Zeb A; Rana I; Choi HI; Lee CH; Baek SW; Lim CW; Khan N; Arif ST; Sahar NU; Alvi AM; Shah FA; Din FU; Bae ON; Park JS; Kim JK
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33291312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein crystals for the delivery of biopharmaceuticals.
    Basu SK; Govardhan CP; Jung CW; Margolin AL
    Expert Opin Biol Ther; 2004 Mar; 4(3):301-17. PubMed ID: 15006725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals.
    Puranik A; Dandekar P; Jain R
    Biotechnol Prog; 2022 Nov; 38(6):e3291. PubMed ID: 35918873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ionic-liquid-based approaches to improve biopharmaceuticals downstream processing and formulation.
    Almeida C; Pedro AQ; Tavares APM; Neves MC; Freire MG
    Front Bioeng Biotechnol; 2023; 11():1037436. PubMed ID: 36824351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 11. The biopharmaceutical industry in China: history and future perspectives.
    Gao K; Wang J
    Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions.
    Ponzio TA; Feindt H; Ferguson S
    LES Nouv; 2011 Sep; 46(3):216-225. PubMed ID: 22162900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon. An overview of the state of basic research with special regard to interferon-gamma].
    Günther G; Otto B
    Arzneimittelforschung; 1993 Feb; 43(2):182-8. PubMed ID: 7681288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic chromatography-based purification strategies accelerate the development of downstream processes for biopharmaceutical proteins produced in plants.
    Buyel JF; Fischer R
    Biotechnol J; 2014 Apr; 9(4):566-77. PubMed ID: 24478119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulations strategies for biopharmaceuticals--ensuring success to market.
    Atkinson EM; Klum W
    IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies.
    Elsayed A; Jaber N; Al-Remawi M; Abu-Salah K
    Int J Pharm; 2023 Oct; 645():123360. PubMed ID: 37657507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of biopharmaceutical proteins by yeast: advances through metabolic engineering.
    Nielsen J
    Bioengineered; 2013; 4(4):207-11. PubMed ID: 23147168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.